Journal Mobile Options
Table of Contents
Vol. 21, No. 3, 2003
Issue release date: 2003
Dig Dis 2003;21:271–275
(DOI:10.1159/000073347)

L-Carnitine in the Treatment of Mild or Moderate Hepatic Encephalopathy

Malaguarnera M. · Pistone G. · Astuto M. · Dell’Arte S. · Finocchiaro G. · Lo Giudice E. · Pennisi G.
aDipartimento di Scienze della Senescenza, Urologiche e Neurologiche, Università degli Studi di Catania, e bDipartimenti di Neuroscienze e cSpecialità Medico-chirurgiche Sez. Anestesiologia, Università di Catania, Italia

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Hepatic encephalopathy (HE) is one of the major complications of cirrhosis. Experimental and clinical findings observed in liver, muscle and brain have provided new insights into the ammonia mechanism of action. L-Carnitine (LC), inducing ureagenesis, may decrease blood and brain ammonia levels. 120 patients meeting inclusion criteria were randomized either to a treatment for 60 days with LC or placebo (2 g twice a day). Previous studies have reported a significant protective effect of LC in mice and rats, which is associated with a significant reduction of blood and brain ammonia concentration, suggesting an action of LC either at peripheral or central sites. Results of our study show a protective effect of LC in ammonia-precipitated encephalopathy in cirrhotic patients. Either in subjects with HE 1 or 2 we observed a significant reduction at day 30 and more markedly at day 60 of treatment. A significant therapeutic effect of LC was also observed in the NCT-A, which is an accepted and reliable psychometric test for the assessment of mental function in cirrhotic patients with HE.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Basile AS, Jones EA: Ammonia and GABAergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997;25:103–105.
  2. Lockwood AH, Yap EWH, Wong WH: Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991;11:337–341.
  3. Tarter RE, Panzak G, Switala J, Lu S, Simkevitz H, Van Thiel D: Isokinetic muscle strength and its association with neuropsychological capacity in cirrhotic alcoholics. Alcohol Clin Exp Res 1997;21:191–196.
  4. Haussinger D, Kircheis G, Fischer R, Schiess F, Von Dahl S: Hepatic encephalopathy in chronic liver disease: A clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000;32:1035–1038.
  5. Ullian EM, Sepperstein SK, Christopherson KS, Barres BA: Control of synapse number by glia. Science 2001;291:657–661.
  6. Noremberg MD: Astrocyte-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996;16:245–253.
  7. Conn HO, Leevy CM, Vlahovic ZR, et al: Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. Gastroenterology 1997;72:573–583.
  8. Bremer J: The role of carnitine in cell metabolism; in De Simone C, Famularo G (eds): Carnitine Today. Heidelberg, Springer, 1997, pp 1–37.
  9. O’Connor JE, Costell M, Grisolia S: Prevention of ammonia toxicity by L-carnitine: Metabolic changes in brain. Neurochem Res 1984;9:563–570.
  10. Therrien G, Rose C, Butterworth J, Butterworth RF: Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portocaval shunted rat. Hepatology 1997;25:551–556.
  11. Reitan RM, Woegson D: The Halstead-Reitan. Neuropsycological test battery: theory and clinical interpretation. Tucson, Neuropsychology Press, 1993.
  12. De Fonseca-Wollheim F: Direkte Plasmaammoniakbestimmung ohne Enteiweissung. J Clin Chem Clin Biochem 1973;11:421–431.
  13. Conn HO, Liebertahl MM: The Hepatic Coma Syndrome and Lactulose. Baltimore, Williams & Wilkins, 1979, pp 1–121.
  14. Conn HO: Trail-making and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977;22:541–550.
  15. Rikkers L, Jenko P, Rudman D, Freides D: Subclinical hepatic encephalopathy: Detection prevalence and relationship to nitrogen metabolism. Gastroenterology 1978;75:462–469.
  16. Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO, McClain CJ: Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980;140:519–521.
  17. Matsouka M, Igsu H, Kohriyama K, Inoue N: Suppression of neurotoxicity of ammonia by L-carnitine. Brain Res 1991;567:328–331.
  18. Atterbury CE, Maddrey WC, Conn HO: Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. Dig Dis 1978;23:398–408.
  19. Hearn TJ, Coleman AE, Lai JCK, Griffith OW, Cooper AJL: Effect of orally administered L-carnitine on blood ammonia and L-carnitine concentrations in portocaval-shunted rats. Hepatology 1989;10:822–828.
  20. Therrien G, Giguere JF, Butterworth RF: Increased cerebrospinal fluid lactate reflects deterioration of neurological status in experimental portal-systemic encephalopathy. Metab Brain Dis 1991;6:231–238.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50